Tolerability of Serotonin Norepinephrine Reuptake Inhibitor Antidepressants

@article{Montgomery2008TolerabilityOS,
  title={Tolerability of Serotonin Norepinephrine Reuptake Inhibitor Antidepressants},
  author={Stuart A. Montgomery},
  journal={CNS Spectrums},
  year={2008},
  volume={13},
  pages={27 - 33}
}
Abstract All three serotonin norepinephrine reuptake inhibitors (SNRIs) inhibit the reuptake of both serotonin and norepinephrine but they do so with differing affinity ratios. Venlafaxine has a 30-fold higher affinity for serotonin than for norepinephrine while duloxetine has a 10-fold selectivity for serotonin. Milnacipran has a balanced (1:1) ratio of potency for inhibition of reuptake of the two neurotransmitters. The most frequent adverse event with SNRIs is nausea. Not unexpectedly… Expand
Antidepressant therapy with milnacipran and venlafaxine
  • L. Mansuy
  • Medicine
  • Neuropsychiatric Disease and Treatment
  • 2010
TLDR
The first head-to-head study compared the therapeutic effects and tolerability of the two antidepressants when flexibly titrated to the high dose of 200 mg/day and showed that the two SNRIs have similar efficacy and safety profiles. Expand
Raising the Minimum Effective Dose of Serotonin Reuptake Inhibitor Antidepressants: Adverse Drug Events
  • D. Safer
  • Medicine
  • Journal of clinical psychopharmacology
  • 2016
TLDR
Strong evidence from fixed-dose trial data for the efficacy of nonascendant, minimum effective doses of SRIs was found for the treatment of both major depression and anxiety disorders, and the finding that most SRI ADEs have an ascending dose-response curve was particularly important. Expand
A review of SSRIs and SNRIs in neuropathic pain
TLDR
SSRIs and SNRIs may be considered in the treatment of neuropathic pain if treatment with tricyclic antidepressants and anticonvulsants fails, or if there are contraindications to these drugs. Expand
Savella® (Milnacipran) Causing Elevated Normetanephrines
TLDR
It was concluded that, in the setting of normal PET, CT, and MIBG scans, the likely source of elevated normetanephrines, and probable cause of worsening hypertension, dizziness, palpitations, and sweating was milnacipran. Expand
Chronic olanzapine, serotonin receptors, and subsequent serotonin toxicity.
TLDR
A case of serotonin toxicity due to the addition of citalopram to chronic therapy with olanzapine is presented and potential mechanisms of the ensuing serotonin toxicity are suggested. Expand
In utero exposure to venlafaxine, a serotonin-norepinephrine reuptake inhibitor, increases cardiac anomalies and alters placental and heart serotonin signaling in the rat.
TLDR
In utero venlafaxine exposure altered the placental index and induced fetal cardiac anomalies in rats, and it is proposed that the increased incidence of cardiac anomalies is mediated through alterations in serotonin signaling in the placenta and fetal heart. Expand
Milnacipran-Associated Urinary Retention A Case Report
TLDR
It is suggested that one should be cautious while using this drug, and patients should be explained about this rare but possible adverse effect of milnacipran. Expand
Effects of selective serotonin‐reuptake inhibitors (SSRIs) on human villous trophoblasts syncytialization
TLDR
It is shown that SSRIs affect villous trophoblast syncytialization in a structure‐ and concentration‐dependent manner and suggests that certainSSRIs may compromise placental health. Expand
Pharmacokinetics of duloxetine self-administered in overdose with quetiapine and other antipsychotic drugs in a Japanese patient admitted to hospital
TLDR
Even if more than 1 h (the generally recommended period) has passed after administration of duloxetine in such overdose cases, gastric lavage and/or administration of activated charcoal may be effective in clinical practice up to 6’h because of the typically slow elimination behavior illustrated by the PBPK model. Expand
SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population.
TLDR
The results suggest that the variation of the SLC6A2 gene is associated with treatment remission after venlafaxine in patients with MDD. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants
Abstract The class of serotonin and norepinephrine reuptake inhibitors (SNRIs) now comprises three medications: venlafaxine, milnacipran, and duloxetine. These drugs block the reuptake of bothExpand
Milnacipran and selective serotonin reuptake inhibitors in major depression
TLDR
Clinical trials comparing the new SNRI milnacipran with the SSRIs fluoxetine and fluvoxamine suggest that milnadrenaline reuptake inhibitors is superior in efficacy to SSRI and is equally well tolerated, and milnACipran, therefore, appears to offer a therapeutic advantage over theSSRIs. Expand
Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability
TLDR
Meta-analyses of the original data of controlled trials involving 1032 patients, comparing milnacipran with imipramine or selective serotonin reuplake inhibitors (SSRIs), show that milnACipran provides antidepressant efficacy similar to that of imipramsine and significantly superior to thatof the SSRIs. Expand
Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine
  • G. Clerc
  • Psychology, Medicine
  • International clinical psychopharmacology
  • 2001
TLDR
It is concluded that milnacipran may offer some advantages over selective serotonin reuptake inhibitors, such as fluvoxamine, in the treatment of moderate to severe major depression. Expand
Cardiovascular Profile of Duloxetine, a Dual Reuptake Inhibitor of Serotonin and Norepinephrine
TLDR
The cardiovascular effects of duloxetine appear to be comparable with medications considered to be first-line options for depression, and no clinically meaningful effect on electrocardiogram profiles in a relatively healthy cohort of clinical trial patients. Expand
Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
  • A. Schatzberg
  • Psychology, Medicine
  • The Journal of clinical psychiatry
  • 2003
TLDR
Duloxetine appears to have significant benefit in the treatment of the painful physical symptoms associated with depression, and it is hoped that duloxettine therapy may reduce the likelihood of depressive relapse. Expand
Efficacy and tolerability of milnacipran: an overview
TLDR
It is suggested that milnacipran offers clinical advantages over TCAs in terms of tolerability, and over SSRIs in termsOf efficacy, and in particular, the lack of cardiovascular adverse events appears to offer advantages in cases of deliberate overdose. Expand
Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data
TLDR
The relative frequency with which venlafaxine and other new antidepressants result in fatal poisoning is established, to establish the relative frequency of the use of newer serotoninergic antidepressants. Expand
Duloxetine and Venlafaxine-XR in the Treatment of Major Depressive Disorder: A Meta-Analysis of Randomized Clinical Trials
TLDR
Venlafaxine-XR tends to have a favorable trend in remission and response rates compared with duloxetine, however, dropout rates and adverse events did not differ and a direct comparison is warranted to confirm this tendency. Expand
Pharmacokinetics of milnacipran in comparison with other antidepressants
TLDR
The pharmacokinetic characteristics of the tricyclic antidepressants, the selective serotonin reuptake inhibitors (SSRIs) and more recently introduced antidepressants such as venlafaxine and nefazodone are reviewed. Expand
...
1
2
3
4
5
...